Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 13.99K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 8.00 shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 7.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was -6.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 8.00K shares, a 199900.00% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 4.00 shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 161.45K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 13.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 8.00 shares 10-Q · filed 2026-05-06 | |
| 2025-12-31 | 7.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 8.00K shares 10-K · filed 2026-03-23 |
| 2024-12-31 | 4.00 shares 10-K · filed 2025-03-31 | |
| 2023-12-31 | -6.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | 0.00 shares 10-K · filed 2024-04-10 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 7.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 161.45K shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 72.00 shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |